Q32 Bio

Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, reporting revenue of $0M (in-line with the pre-revenue biotech model) vs. an expected $0.6M, while GAAP EPS of -$0.44 significantly outperformed the -$0.542 expectation. The company ended the quarter with $106.3M in cash, and a subsequent $200M public offering in July 2026 has extended the financial runway through Phase 3 topline results. The focus remains on the Bempikibart program, with a registration-directed trial expected to initiate in 1H 2027.